What is the 13F Pro Quality Score for LGVN?

13F Pro ranks Longeveron Inc. (LGVN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LGVN's current score at https://13fpro.ai/company/LGVN (free sign-up required for the full ranking).

Where does 13F Pro source LGVN data?

All Longeveron Inc. fundamentals and ownership data come directly from SEC EDGAR. Longeveron Inc. files with the SEC under CIK 1721484. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LGVN in?

Longeveron Inc. (LGVN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LGVN research updated on 13F Pro?

LGVN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Longeveron Inc.(LGVN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1721484 LGVN stock profile & AI dashboard →

13F Pro Quality Score

11.8/100

Rank #2,893 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why LGVN Scores 12/100

exact factor attribution · 2026-09-11

LGVN's composite is driven by institutional flow, held back by revenue growth and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

+2.3 pts

96th pct

Earnings growth

-2.2 pts

5th pct

Shareholder dilution

-2.3 pts

5th pct

Earnings quality

-2.8 pts

22th pct

Capital efficiency

-4.8 pts

2th pct

Profitability

-6.9 pts

4th pct

Free cash flow

-7.0 pts

4th pct

Scale

-7.1 pts

3th pct

Revenue growth

-7.4 pts

13th pct

Latest change (2026-08-13): 17 → 13 · ↓ Revenue growth 50→26

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

LGVN Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Longeveron Inc. (LGVN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LGVN at 11.8/100 on a 32-signal composite quality model, placing it at rank #2,893 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Longeveron Inc. reports quarterly revenue of $287.0K, net income of $-6.1M, free cash flow of $-5.8M. Top institutional holders of LGVN by reported 13-F value include MILLENNIUM MANAGEMENT, Logos Global Management, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. LGVN trades on the Nasdaq exchange and files with the SEC under CIK 1721484. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LGVN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Longeveron Inc. directly from SEC EDGAR. Longeveron Inc.'s 13F Pro composite quality score has ranged between 11 and 17 since 2026, currently 11.8 — a declining long-term trajectory across 9 quarterly and live scoring snapshots.

✦

Fun facts about Longeveron Inc.

Quirks, history, and lore behind LGVN — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Miami, Florida · focused on aging-related diseases.
2
The Numbers
A micro-cap with minimal revenue, it runs on grant funding and equity raises — the typical financial profile of a company betting everything on its pipeline.
3
The History
Founded in 2016 as a spinout of research from the University of Miami, it was built around the idea that getting old is, medically speaking, a problem worth solving.
4
The Secret
Its core platform uses cardiac stem cells — specifically cells called Lomecel-B — to target conditions associated with frailty and aging of the heart and brain.
5
The Lore
It has conducted clinical trials in Alzheimer's disease and aging frailty, and even explored its stem cell therapy in the context of COVID-19 complications.
6
The Giveaway
The name literally means "long life" — this Miami-based longevity biotech is betting that Lomecel-B can make your golden years a little less rusty.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$287.0K

Net Income

Q2 2026

$-6.1M

Free Cash Flow

Q2 2026

$-5.8M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-49.9% YoY

$1.2MFY 2025

FY22 $1.2MFY23 $709.0KFY24 $2.4MFY25 $1.2M

Net Income

-42.1% YoY

$-22.7MFY 2025

FY22 $-18.8MFY23 $-21.4MFY24 $-16.0MFY25 $-22.7M

Operating Income

-40.9% YoY

$-23.3MFY 2025

FY22 $-18.0MFY23 $-21.0MFY24 $-16.5MFY25 $-23.3M

EPS (Diluted)

+50.8% YoY

$-1.29FY 2025

FY22 $-0.90FY23 $-10.22FY24 $-2.62FY25 $-1.29

Total Assets

-59.9% YoY

$10.3MFY 2025

FY22 $27.4MFY23 $12.1MFY24 $25.6MFY25 $10.3M

Total Debt

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Op. Cash Flow

-34.4% YoY

$-18.6MFY 2025

FY22 $-14.0MFY23 $-19.0MFY24 $-13.9MFY25 $-18.6M

Free Cash Flow

-30.1% YoY

$-18.9MFY 2025

FY22 $-14.5MFY23 $-19.3MFY24 $-14.5MFY25 $-18.9M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$1.2M -49.9%	$2.4M +237.4%	$709.0K -42.0%	$1.2M -6.4%	$1.3M -76.8%	$5.6M
Net Income	$-22.7M -42.1%	$-16.0M +25.4%	$-21.4M -13.7%	$-18.8M -10.5%	$-17.0M -358.1%	$-3.7M
Operating Income	$-23.3M -40.9%	$-16.5M +21.4%	$-21.0M -16.5%	$-18.0M -3.4%	$-17.5M -362.0%	$-3.8M
EPS (Diluted)	$-1.29 +50.8%	$-2.62 +74.4%	$-10.22 -1035.6%	$-0.90 +0.0%	$-0.90	—
Total Assets	$10.3M -59.9%	$25.6M +111.6%	$12.1M -55.9%	$27.4M -35.9%	$42.8M +362.8%	$9.2M
Total Debt	—	—	—	—	—	$450.0K
Operating Cash Flow	$-18.6M -34.4%	$-13.9M +27.0%	$-19.0M -36.0%	$-14.0M -45.0%	$-9.6M -307.6%	$-2.4M
Free Cash Flow	$-18.9M -30.1%	$-14.5M +24.8%	$-19.3M -32.8%	$-14.5M -45.9%	$-10.0M -299.4%	$-2.5M

Get alerted when LGVN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Longeveron Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LGVN

MILLENNIUM MANAGEMENT LLC
$951.8K1,353,881 sh
Logos Global Management LP
$904.8K1,287,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$408.7K581,305 sh
BlackRock, Inc.
$157.6K224,170 sh
GEODE CAPITAL MANAGEMENT, LLC
$143.2K203,761 sh
JANE STREET GROUP, LLC
$133.8K190,370 sh
VANGUARD FIDUCIARY TRUST CO
$98.5K140,127 sh
Mariner, LLC
$88.6K126,000 sh
ADAR1 Capital Management, LLC
$76.2K108,406 sh
Beacon Pointe Advisors, LLC
$70.3K100,000 sh

Fund	Value	Shares
MILLENNIUM MANAGEMENT LLC	$951.8K	1,353,881
Logos Global Management LP	$904.8K	1,287,000
VANGUARD CAPITAL MANAGEMENT LLC	$408.7K	581,305
BlackRock, Inc.	$157.6K	224,170
GEODE CAPITAL MANAGEMENT, LLC	$143.2K	203,761
JANE STREET GROUP, LLC	$133.8K	190,370
VANGUARD FIDUCIARY TRUST CO	$98.5K	140,127
Mariner, LLC	$88.6K	126,000
ADAR1 Capital Management, LLC	$76.2K	108,406
Beacon Pointe Advisors, LLC	$70.3K	100,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LGVN on your watchlist

Track score changes the day Longeveron Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LGVN a good stock to buy?

13F Pro's AI-powered analysis of Longeveron Inc. (LGVN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LGVN are available on the LGVN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. LGVN is classified as a small company.

Which hedge funds own LGVN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LGVN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Longeveron Inc.'s investment landscape.